Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published Date October 2007 Volume 2007:3(4) Pages 381—388

DOI

Published 4 October 2007

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Intravitreal ranibizumab in treating extensive traumatic submacular hemorrhage

Abdul-Salim I, Embong Z, ST Khairy-Shamel, Raja-Azmi MN

Clinical Ophthalmology 2013, 7:703-706

Published Date: 9 April 2013

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:865-876

Published Date: 27 March 2013

Functionalized carbon nanotubes: biomedical applications

Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR

International Journal of Nanomedicine 2012, 7:5361-5374

Published Date: 9 October 2012

Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections

Grazú V, Silber AM, Moros M, Asín L, Torres TE, Marquina C, Ibarra MR, Goya GF

International Journal of Nanomedicine 2012, 7:5351-5360

Published Date: 8 October 2012

Characterization of drug-release kinetics in trabecular bone from titania nanotube implants

Aw MS, Khalid KA, Gulati K, Atkins GJ, Pivonka P, Findlay DM, Losic D

International Journal of Nanomedicine 2012, 7:4883-4892

Published Date: 12 September 2012

Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre- or poststeroid pulse treatment

Kimihito Maeda, Yuichiro Ohara, Masato Hashimoto, Hiroshi Ohguro

Clinical Ophthalmology 2008, 2:609-612

Published Date: 5 October 2008

Early vascular aging (EVA): consequences and prevention

Peter M Nilsson

Vascular Health and Risk Management 2008, 4:547-552

Published Date: 30 June 2008

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Vascular Health and Risk Management 2007, 3:967-973

Published Date: 15 January 2007

A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice

Maddalena Veronesi, Arrigo FG Cicero, Maria Grazia Prandin, Ada Dormi, Eugenio Cosentino, et al

Vascular Health and Risk Management 2007, 3:999-1005

Published Date: 15 January 2007

Choroidal neovascular membrane following clear lens extraction

Banu Turgut Öztürk, Hürkan Kerimoglu, Ümit Kamis, Saban Gönül, Süleyman Okudan

Clinical Ophthalmology 2007, 1:559-561

Published Date: 11 January 2007